Clinical and laboratory parameters were assessed at baseline, week 24, and week 96. CD4+ T cell count was measured by single- and dual-platform flow cytometry (Becton-Dickinson). HIV-1 RNA in plasma was performed using the COBAS AMPLICOR HIV-1 Monitor Test v1.5 or COBAS TaqMan HIV-1 Test v2.0 (Roche Molecular Systems), with lower limits of quantification (LLQ) of 50 and 20 copies/mL, respectively. CSF samples were run in batch and diluted fourfold for volume requirements for detection of HIV-1 RNA, with an LLQ of 80 copies/mL using the TaqMan platform. HIV-1 RNA measurements below the LLQ that tested positive were designated detectable but not quantifiable. Neuropsychological testing was performed at standardized intervals at weeks 0, 12, 24, and 96 [11 (link)].